Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies

• Published in: Molecular biology reports Vol. 48; no. 1; pp. 875 - 886
• Main Authors: Dib, Israa, Khalil, Alia, Chouaib, Racha, El-Makhour, Yolla, Noureddine, Hiba
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 2021; Springer Nature B.V
• Subjects: 3' Untranslated Regions; Animal Anatomy; Animal Biochemistry; APOC3 gene; Apolipoprotein C-III; Apolipoprotein C-III - antagonists & inhibitors; Apolipoprotein C-III - blood; Apolipoprotein C-III - genetics; Apolipoproteins; Arteriosclerosis; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - pathology; Biomedical and Life Sciences; Cardiovascular Agents - therapeutic use; Cardiovascular diseases; Cell proliferation; Clinical Trials as Topic; Dyslipidemia; Gene Expression; Gene polymorphism; Histology; Humans; Hyperlipoproteinemia Type I - blood; Hyperlipoproteinemia Type I - drug therapy; Hyperlipoproteinemia Type I - genetics; Hyperlipoproteinemia Type I - pathology; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Hypertriglyceridemia - genetics; Hypertriglyceridemia - pathology; Infectious diseases; Life Sciences; Lipoproteins; Molecular modelling; Morphology; Oligonucleotides - therapeutic use; Plaque, Atherosclerotic - blood; Plaque, Atherosclerotic - drug therapy; Plaque, Atherosclerotic - genetics; Plaque, Atherosclerotic - pathology; Plasma levels; Polymorphism, Genetic; Review; Risk Factors; Smooth muscle; Structure-function relationships; Triglycerides; Triglycerides - blood; CVD; SstI polymorphism; apoC-III; Hypertriglyceridemia; Atherosclerosis
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-020-06071-5

Cardiovascular diseases (CVD) have overtaken infectious diseases and are currently the world’s top killer. A quite strong linkage between this type of ailments and elevated plasma levels of triglycerides (TG) has been always noticed. Notably, this risk factor is mired in deep confusion, since its role in atherosclerosis is uncertain. One of the explanations that aim to decipher this persistent enigma was provided by apolipoprotein C-III (apoC-III), a small protein historically recognized as an important regulator of TG metabolism. Preeminently, hundreds of studies have been carried out in order to explore the APOC3 genetic background, as well as to establish a correlation between its variants and dyslipidemia-related disorders, pointing to an earnest predictive power for future outcomes. Among several polymorphisms reported within the APOC3 , the SstI site in its 3′-untranslated region (3′-UTR) was the most consistently and robustly associated with an increased CVD risk. As more genetic data supporting its importance in cardiovascular events aggregate, it was declared, correspondingly, that apoC-III exerts various atherogenic effects, either by intervening in the function and catabolism of many lipoproteins, or by inducing endothelial inflammation and smooth muscle cells (SMC) proliferation. This review was designed to shed the light on the structural and functional aspects of the APOC3 gene, the existing association between its SstI polymorphism and CVD, and the specific molecular mechanisms that underlie apoC-III pathological implications. In addition, the translation of all these gathered knowledges into preventive and therapeutic benefits will be detailed too.